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Immune recognition is coupled to powerful proinfl  ammatory effector pathways 
that must be tightly regulated. The ancient alternative pathway of complement 
activation is one such proinfl  ammatory pathway. Genetic susceptibility factors 
have been identifi  ed in both regulators and activating components of the alter-
native pathway that are associated with thrombotic microangiopathies, glomer  u-
lonephritides, and chronic conditions featuring debris deposition. These 
observations indicate that excessive alternative pathway activation promotes 
thrombosis in the microvasculature and tissue damage during debris accumu-
lation. Intriguingly, distinct genetic changes in factor H (FH), a key regulator of 
the alternative pathway, are associated with hemolytic uremic syndrome (HUS), 
membranoproliferative glomerulonephritis (dense deposit disease), or age-related 
macular degeneration (AMD). A mouse model of HUS designed to mirror human 
mutations in FH has now been developed, providing new understanding of the 
molecular pathogenesis of complement-related endothelial disorders.
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Types of HUS
HUS and thrombotic thrombocytope-
nia purpura (TTP) constitute a group 
of diseases known as thrombotic micro-
angiopathies in which organ damage re-
sults from platelet aggregation and fi  brin 
plugs in small vessels. HUS, in particular, is 
characterized by microangiopathic hemo-
lytic anemia (damage to red blood cells as 
they travel through narrowed capillaries), 
consumptive thrombocytopenia (exhaus-
tion of platelets as they become enmeshed 
in platelet-fi  brin thrombi), and microvas-
cular glomerular thrombosis (formation of 
thrombi in the kidney). The thrombotic 
microangiopathy is particularly severe 
in the renal microvasculature and leads 
to acute renal failure. TTP shares these 
features, but neurologic dysfunction dom-
inates the clinical presentation. Patients 
with TTP carry mutations in the metal-
loproteinase ADAMTS13 or have auto-
antibodies against this metalloproteinase, 
allowing for an etiologic distinction be-
tween TTP and HUS.
The most common form of HUS is 
associated with a diarrheal illness caused 
by infection with strains of Escherichia coli 
that produce Shiga-like toxins (Stx-1 and 
Stx-2) and hence is called Stx-HUS or 
diarrhea-positive HUS. Less common is 
atypical HUS (aHUS) in which there is 
no preceding diarrhea (nonenteropathic 
HUS). Precipitating factors commonly 
implicated in the pathogenesis of aHUS 
include infections, use of endothelial-
damaging drugs, malignancies, transplan-
tation, and pregnancy. These triggers can 
all cause endothelial cell activation and 
injury. Although there is some patho-
physiologic overlap, Stx-HUS–induced 
pathology is predominant in the glo-
merulus, whereas the predominant pa-
thology in aHUS involves the renal 
and interlobular arterioles. The progno-
sis of Stx-HUS is favorable, with the 
majority of patients recovering renal 
function, whereas in aHUS there is 25% 
acute mortality and most of the survi-
vors develop end-stage renal disease.
Familial occurrence of aHUS has 
been recognized for many years (1). In-
heritance was thought to be predomi-
nantly recessive, but it is now recog  nized 
that most families feature dominant in-
heritance with  50% penetrance. In 
1998, Warwicker et al. (2) published the 
results of a linkage study in three families 
with aHUS. This pivotal study showed 
segregation of the disease to the q32 
region of chromosome 1, which contains 
genes that regulate complement activa-
tion. A possible link between complement 
abnormalities and aHUS had also been 
recognized for many years. One study in 
particular showed that low levels of the 
complement protein C3 and glomerular 
deposition of C3 fragments were associ-
ated with disease (3). However, these 
clinical reports were not widely appre-
ciated, as most patients had normal levels 
of circulating complement. And a role 
for innate immunity was not considered.
aHUS mutations have since been 
described in the genes encoding fi  ve 
complement proteins, including FH, 
membrane cofactor protein/CD46 
(MCP), factor I (FI), factor B (FB), and 
C3 (4–8). Functional studies have shown 
that the mutations in the three regula-
tors FH, FI, and MCP lead to loss of 
function and thus more complement 
activation, whereas the mutations in FB 
are gain of function. This has provided 
unequivocal evidence that complement 
dysregulation is involved in the pathology 
of aHUS. With this knowledge in hand, 
Pickering et al. (9) have now developed 
a faithful model of human aHUS in an 
FH-defi   cient mouse. The new mouse 
model, described in this issue (p. 1249), 
is suffi   ciently “human-like” so that key 
questions related to immune pathogen-
esis can now be addressed and potential 
therapeutic interventions assessed.
Alternative pathway of complement 
activation
The complement system (as one of our 
students recently informed us) is “a 
simple little proteolytic cascade when 
compared with cytokine biology and 
signal transduction pathways.” It is an 1246  MOUSE MODEL OF HUS | Atkinson and Goodship
ancient innate immune network of plasma 
proteins that began evolutionarily as a 
host defense system of hemolymph. The 
goal of the oldest cascade, the alternative 
pathway, is to rapidly coat invading 
microbes with large quantities of the 
opsonic complement fragment C3b 
(Fig. 1 A). This process is facilitated by 
a feedback or amplifi  cation loop that 
allows several million molecules of C3b 
to be deposited on bacteria within a few 
seconds. Complement activation also 
occurs, albeit usually in a more limited 
fashion, on altered self-tissue, such as on 
cells undergoing apoptosis and at sites of 
injury and infection. To prevent the 
accumulation of undesirable quantities 
of deposited C3b, the host synthesizes a 
family of regulatory proteins that inhibit 
the feedback loop both on cell surfaces 
and in plasma. These regulatory proteins 
are particularly designed to prevent C3 
activation, and heterozygous mutations 
(haploinsuffi   ciency) in these regulators 
predispose humans to aHUS. In individ-
uals carrying these mutations, expression 
of even 50% of normal levels of these 
inhibitors is inadequate to prevent dis-
ease at times of injury and stress in the 
renal microvasculature.
FH
The fi  rst candidate gene in the regula-
tors of complement activation (RCA) 
cluster that was linked to aHUS was FH, 
a complement control protein (CCP) 
that protects host tissue from comple-
ment attack (2, 4). The surfaces of 
“foreign” particles, such as viruses and 
bacteria, are vulnerable to complement 
activity, as they lack FH and other com-
plement regulatory proteins. FH regu-
lates the feedback loop in three ways. It 
is a cofactor for the serine protease FI, 
which cleaves C3b. This cleavage reac-
tion produces a fragment, iC3b, which 
has no hemolytic or amplifi  cation po-
tential (Fig. 1 B). Second, FH both 
prevents the formation of and acceler-
ates the disassociation of the alternative 
pathway C3 convertase, C3bBb. Finally, 
FH binds to polyanions on host cell 
surfaces and tissue matrices, such as base-
ment membranes, thus blocking deposi-
tion of C3b. FH and other proteins 
within the RCA cluster share a common 
structural motif consisting of contigu-
ous, homologous, independently folding 
modules called short consensus repeats 
or CCP modules. FH consists of 20 such 
repeats of  60 amino acids each that 
are held together by short 2– to 6–amino 
acid linkers.
Previous reports had shown a possible 
association between aHUS and reduced 
plasma concentrations of FH (10, 11). 
Mutations in the FH gene in aHUS 
  patients have now been widely described. 
The interactive FH-HUS mutation data-
base (http://www.FH-HUS.org) lists 71 
disease-associated mutations (12). These 
are present in  30% of patients, includ-
ing those with sporadic and familial forms 
of the disease. The majority are hetero-
zygous missense mutations that cluster 
in the carboxyl-terminal exons and are 
associated with normal levels of circu-
lating FH. The remaining mutations are 
mostly heterozygous deletions or mis-
sense mutations that result in either a 
truncated protein or impaired secretion 
of the protein and thus cause a 50% 
reduction in plasma levels of FH.
This clustering of missense muta-
tions in the C-terminal region, which is 
crucial for FH binding to host surfaces, 
is remarkable. Functional and structural 
studies of mutants indicate that the re-
duced interaction between FH and cell 
surfaces leads to ineffi   cient  cofactor 
activity (12).
There are two existing animal models 
of total FH defi  ciency: the Norwegian 
Yorkshire pig (13) and a knockout mouse 
model (14). In both, the defi  cient animals 
develop membranoproliferative glomeru-
lonephritis rather than HUS. This form 
of glomerulonephritis is similar to the 
disease seen in humans with homozygous 
FH defi  ciency in which dense deposits 
of C3 fragments accumulate in the glo-
merulus (15). This illness can present in a 
variety of ways, including asymptom-
atic urinary abnormalities, nephrotic 
syndrome, and chronic kidney disease. 
Patients with membranoproliferative glo-
mer  ulonephritis also develop ocular le-
sions similar to those seen in AMD. A 
series of studies has shown that polymor-
phisms in the FH gene are associated 
with increased susceptibility to AMD 
(16–19). In particular, a polymorphism 
in exon 9 (rs1061107:1277T>C) that 
results in a tyrosine to histidine change 
(Y402H) in the seventh CCP, has been 
shown to be a susceptibility factor in all 
these studies.
A murine model of aHUS
In this issue, Pickering et al. describe a 
mouse model of aHUS in which the dis-
ease is remarkably similar to that seen in 
human patients. Taking advantage of the 
FH−/− mouse they had previously devel-
oped (14), the group produced a trans-
genic mouse in which the FH gene lacks 
Figure 1.  Activation and inactivation of the alternative complement pathway. (A) C3b binds 
FB, which is then converted to Bb, by the serine protease factor D (not depicted). The resulting C3bBb 
is the alternative pathway C3 convertase that cleaves additional C3 to C3b, thus amplifying the 
process. Properdin stabilizes this convertase (not depicted). (B) This process is controlled by regulatory 
proteins such as FH. It decays Bb from C3b and is a cofactor for degradation of C3b to iC3b by the 
serine protease FI. FH attaches to surfaces through its heparin/anionic-binding sites in its carboxyl-
terminus (CCPs 16–20) while the decay-accelerating activity and cofactor activity sites are at the 
amino terminus (CCPs 1–4).COMMENTARY
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the exons encoding the fi  ve C-terminal 
CCP modules. As noted above, in humans 
with FH-associated aHUS, a majority of 
the mutations occur in these C-terminal 
repeats and disrupt a heparin-binding site.
Homozygous FH-defi  cient  mice 
have very low circulating levels of C3 and 
FB because these proteins are consumed 
as a result of excessive complement acti-
vation. Consequently, these mice have 
minimal complement-activating capacity. 
By introducing the C-terminal trunca-
tion of FH into the FH knockout ani-
mals, Pickering et al. restored the control 
of complement activation in the fl  uid 
phase. As a result, the mice did not de-
velop glomerulonephritis, and their cir-
culating levels of C3b and FB were 
partially restored. The combination of 
functional alternative pathway activation 
coupled with a defi  ciency in the capacity 
of FH to bind anionic targets led to spon-
taneous aHUS in mice homozygous for 
the transgene (Cfh−/−.FH∆16-20). Many 
parameters of disease in the mice, includ-
ing the hematologic abnormalities and 
glomerular pathology, closely resembled 
human aHUS. Of note, however, the 
mice heterozygous for expression of the 
mutated FH (Cfh+/−.FH∆16-20; i.e., 
50% of FH carrying the deletion of CCPs 
16–20 and 50% WT FH), which most 
closely resembles the situation in humans, 
did not develop aHUS. As Pickering et al. 
comment, it is becoming apparent that 
aHUS in humans is not a straightforward 
monogenic disease, but rather a disease in 
which mutations may be found in more 
than one complement gene in an indi-
vidual patient. Thus, such mutations must 
be considered to be predisposing rather 
than causative, as a triggering factor is 
necessary to initiate the disease (12). This 
murine model of aHUS aff  ords a unique 
opportunity to resolve some of the co-
nundrums of aHUS. The model will also 
facilitate testing of novel therapies, such as 
targeted complement inhibitors.
Other complement proteins implicated 
in HUS
In the second of the original three 
families reported by Warwicker et al., 
a mutation in MCP was identifi  ed (5). 
Screening of multiple cohorts estab-
lished that  15% of patients with aHUS 
have a mutation (usually heterozygous) in 
the MCP gene (12). MCP is expressed by 
most cells and, like FH, acts as a cofactor 
for the inactivation of C3b. The activity 
of MCP is intrinsic, meaning that it only 
has cofactor activity for C3b when it is 
bound to the same cell (20). An analysis 
of the initial 25 MCP mutations in aHUS 
patients has recently been reported (21).
Mutations in FI, the protease required 
for C3b cofactor activity, also predis-
pose to aHUS. Heterozygous changes 
in FI account for  5% of the known 
mutations in aHUS (6, 22). FI is a disul-
phide-linked, two-chain serine protease 
con  sisting of a 55-kD heavy chain and 
a catalytic 38-kD light chain. FI cleaves 
C3b but only if C3b is associated with 
a cofactor protein such as FH or MCP 
(Fig. 1 B; reference 22).
Mutations in FB were also recently 
described in two families (7). One mu-
tation stabilized the alternative pathway 
C3 convertase by increasing the affi   nity 
of the interaction between FB and C3b. 
The other mutation made the C3bBb 
enzyme complex more resistant to decay. 
Both mutations resulted in increased 
activation of the alternative pathway. 
Mutations in C3 itself have also been 
described in a select group of aHUS 
  patients with low C3 concentrations in 
their plasma but without mutations in 
FH, MCP, FI, or FB (8).
Immunopathogenesis of HUS
These analyses of aHUS-causing muta-
tions in complement proteins establish 
several points of interest. First, although 
FH and MCP both harbor cofactor 
activity for FI, they do not have over-
lapping activity, as mutations in either 
protein predispose to disease in the re-
nal microvasculature. It is also clear that 
half the normal levels of FH, MCP, or 
FI is not suffi   cient to protect the renal 
endothelium after injury (i.e., there is an 
evolutionary reason why these proteins 
are maintained at a certain level and not 
50% less). In addition, anionic (heparin)-
binding sites are required for FH to 
efficiently bind to damaged cells, ex-
posed tissue matrices, and the basement 
membrane, and thus to prevent a throm-
bomicroangiopathy. It is noteworthy that 
the above insights came about by screen-
ing the human genome in multiplex 
fam  ilies. The common theme that 
emerges relative to the specifi  c func-
tional defi  ciency in these complement 
regulators is a decrease in overall co-
factor activity for C3b.
We hypothesize that Stx-HUS also 
follows the same sequence of events. The 
major diff  erence between the Stx-HUS 
and aHUS may be secondary to the de-
gree or type of damage to the endothe-
lium required to cause disease. Less injury 
may be suffi   cient to cause aHUS in indi-
viduals with predisposing mutations, such 
as those in FH. A more severe degree of 
injury, such as that caused by Shiga tox-
ins, may be required for HUS associated 
with  E. coli epidemics. However, it is 
important to note that only 10–15% of 
patients in these epidemics develop HUS 
(23). Minor variations in the expression 
levels or functional activity of one or 
more members of the alternative path-
way may be one explanation for this 
fi  nding. We recently identifi  ed a young 
girl with a heterozygous mutation in 
MCP who developed Stx-HUS. E. coli 
O157:H7 was isolated from her stool, 
and Shiga toxin was identifi   ed in her 
blood and stool. The patient died 4 days 
after presentation. At autopsy, she had 
multiorgan failure secondary to a diff  use 
micro  thromboangiopathy. This informa-
tive case illustrates the interplay between 
a predisposing regulatory protein defi  -
ciency and the potency of the trigger in 
the pathogenesis of HUS.
We still have much to learn about the 
interplay among endothelial injury/stress, 
complement activation, and thrombosis 
in the microvasculature. The “Pickering 
model” of aHUS will allow many ques-
tions to be addressed. What, for example, 
is the nature of the damage induced 
by bacterial toxins and other triggers? 
Which parts of the complement activa-
tion cascade (opsonins, anaphylotoxins, 
membrane attack complex) induce 
thrombosis? How do the complement 
and clotting systems interact, and what 
is unique about the kidney microvascu-
lature? This fi  eld of investigation was 
broken open by analyzing a few families 
using whole genome screens. Based on 
these fi  ndings, a mouse model has now 
been developed that can be used to 1248  MOUSE MODEL OF HUS | Atkinson and Goodship
address outstanding questions about 
the pathogenesis and treatment of this 
complex human disease.
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